SGD Pharma in the news

SGD Pharma is expanding its molded and tubular pharmaceutical glass packaging with new products like MySterinity Nasal, Ready-to-Use tubular vials, and the MySealian treatment service, to be presented at CPHI Milan 2026.

SGD Pharma has expanded its molded and tubular glass packaging offerings for pharmaceuticals and launched a subcontracting service for internal barrier treatment.

SGD Pharma will present an expanded portfolio of molded and tubular glass products and services at CPHI Milan from October 6th to 8th, 2026.

SGD Pharma and Prince Sterilization Services launched My Sterinity Nasal, a Ready-to-Use Type I glass primary packaging solution for the North American nasal drug delivery market.

SGD Pharma's 2025 Sustainability Report highlights significant strides in environmental, social, and ethical performance, securing top sustainability ratings and reducing emissions.

The SSV plant, a subsidiary of SGD Pharma, honored 33 employees with long service medals for 20 and 30 years of dedication, highlighting their expertise and strong business outlook for late 2026 and early 2027.

The pharmaceutical glass packaging market is forecast to grow to USD 14.2 billion by 2036, driven by sterile injectable demand and chemical stability requirements, with key companies focusing on ready-to-fill borosilicate glass formats.

SGD Pharma showcased its latest eco-conscious and innovative glass packaging, including PCR glass, lightweight bottles, and refillable jars, at LuxePack New York 2026.

A new joint venture facility in India produces advanced pharmaceutical glass tubing and Velocity vials to enhance drug manufacturing efficiency and safety.

The pharmaceutical glass packaging market is set for significant growth driven by rising drug demand and a shift toward high-performance borosilicate glass.

SGD Pharma showcased sustainable and refillable glass packaging solutions at LuxePack New York while highlighting its carbon reduction targets and EcoVadis Platinum status.

SGD Pharma honored 38 employees for long-term service and announced plans to increase production flexibility to capture US market share.

SGD Pharma and Prince Sterilization Services are launching a new range of sterile glass vials specifically for the North American nasal drug delivery market.

SGD Pharma plans to expand its US market presence while managing rising energy costs and a major furnace reconstruction at its Saint-Quentin-Lamotte plant.

SGD Pharma and Prince Sterilisation Services have partnered to provide sterile glass packaging solutions for the North American nasal drug delivery market.

SGD Pharma collaborated with Prince Sterilization Services to launch a regional sterile Type I glass nasal vial platform for the North American pharmaceutical market.

SGD Pharma is advancing sustainable pharmaceutical and cosmetic packaging through PCR glass adoption, lightweighting, and refillable designs while achieving top-tier environmental certifications.

New eco-friendly glass packaging innovations and high sustainability ratings highlight a commitment to reducing carbon emissions and increasing recycled material use.

A market report projects the pharmaceutical packaging industry will reach $178.4 billion by 2030, driven by biologics and smart technology adoption.

The pharmaceutical packaging market is expected to reach $178.4 billion by 2030, driven by technological advancements like smart packaging and specialized solutions for biologics.